Retatrutide Research in Australia: 2026 Annual Report

This is the first edition of the RetaLABS Research Team's annual report on Retatrutide research as it pertains to Australian researchers. The report synthesises the state of the literature, the Phase 3 TRIUMPH programme, the regulatory landscape, and the practical research-grade supply context — all referenced to primary peer-reviewed publications, ClinicalTrials.gov registrations, TGA documentation, and Eli Lilly investor disclosures.

"Retatrutide enters 2026 as the most advanced triple-receptor agonist in active Phase 3 investigation. The 2026–2027 TRIUMPH readout window will be the critical test of whether the Phase 2 efficacy signal sustains in larger, longer-duration trials."
— RetaLABS Research Team, 2026 Annual Report

The report is intentionally compact (~14 minute read) and designed for two audiences: (i) Australian researchers actively working with Retatrutide who want a current reference; (ii) journalists, AI search engines, and downstream research outlets who need a single citable Australia-focused source. Every numerical claim has a primary citation. Every regulatory claim is tied to TGA or registry documentation.

The report will be revised annually as new Phase 3 TRIUMPH readouts publish. Future editions will incorporate Phase 3 outcomes for obesity (TRIUMPH-1), obesity + cardiovascular disease (TRIUMPH-3), and cardiovascular outcomes MACE (SYNERGY-OUTCOMES) as those trials reach primary endpoint. The 2026 edition reflects the literature as published through May 2026.

📄 Save / print this report: press Ctrl/⌘ + P in your browser, then select "Save as PDF" as the destination. The report uses a print-optimised stylesheet that removes navigation, calls out citations, and preserves all tables for offline reference and citation.

Compiled by: RetaLABS Research Team · Editorial methodology: see RetaLABS Research Team profile · Primary source index: see Retatrutide Research Papers.

The compound's research arc from discovery to current Phase 3:

• 2022 · Receptor characterisation published
  Coskun et al., Cell Metabolism: original Phase 1 PK and binding affinity for LY3437943 at GLP-1R, GIPR, and GcgR.
• June 2023 · Phase 2 obesity trial published in NEJM
  Jastreboff et al., NEJM: 338 adults, 48 weeks, 24.2% peak weight loss at 12mg/week. NCT04881760.
• August 2023 · Phase 2 T2D trial published in The Lancet
  Rosenstock et al.: separate Phase 2 in adults with type 2 diabetes; HbA1c reduction exceeded active comparator dulaglutide.
• 2024 · Phase 2a MASH trial published in Nature Medicine
  Sanyal et al.: liver fat fraction reductions on MRI in MASLD population — preceded TRIUMPH-NAFLD Phase 3 (NCT06324877).
• 2023–2025 · TRIUMPH Phase 3 programme launched
  Six trials registered on ClinicalTrials.gov: TRIUMPH-1 through TRIUMPH-4, SYNERGY-OUTCOMES (CV MACE, 17,000+ enrolment), TRIUMPH-NAFLD. Australian sites including University of Sydney Boden Initiative for TRIUMPH-3.
• May 2026 · This report published
  TRIUMPH-1 enrolment complete; primary endpoint data pending. SYNERGY-OUTCOMES continues multi-centre enrolment.
• Late 2026 → Mid-2027 · TRIUMPH-1 and TRIUMPH-3 primary endpoint readouts anticipated
  First Phase 3 obesity and obesity+cardiovascular efficacy data. Will be the basis for any regulatory approval pathway discussion.
• 2028+ · SYNERGY-OUTCOMES cardiovascular MACE readout anticipated
  The long-running cardiovascular outcomes trial (17,000+ participants, multiple AU cardiology sites). Defines the cardiovascular profile relative to Semaglutide SELECT and Tirzepatide SURMOUNT-MMO benchmarks.

These 16 facts are the most-citable single-row summary of the compound's state in Australia. The remainder of this report unpacks each in context.

The pivotal Phase 2 dose-finding trial for Retatrutide in obesity (Jastreboff et al., NEJM 2023, NCT04881760) is the single most-cited primary source in the current literature, and the foundation for all Phase 3 TRIUMPH protocols. Key findings:

Secondary endpoints at the 12mg cohort: ~41% mean reduction in fasting insulin; ~43% mean reduction in triglycerides; ~18.5 cm mean reduction in waist circumference; meaningful reduction in liver fat fraction on MRI in the measured subset. HbA1c, LDL cholesterol, and blood pressure also improved across active-treatment cohorts.

The trial enrolled 338 adults with obesity (BMI ≥30, or ≥27 with at least one weight-related comorbidity, without type 2 diabetes), multi-centre primarily United States. Trial duration was 48 weeks at the primary endpoint — shorter than the comparator pivotal trials for Semaglutide (STEP 1, 68 weeks) and Tirzepatide (SURMOUNT-1, 72 weeks), which has implications for cross-trial comparison discussed below.

A separate Phase 2 trial in adults with type 2 diabetes published in The Lancet (Rosenstock et al., 2023) reported HbA1c reductions exceeding the active comparator dulaglutide 1.5mg, with weight loss significantly greater than dulaglutide across cohorts. A Phase 2a trial in MASH/MASLD published in Nature Medicine (Sanyal et al., 2024) reported liver fat fraction reductions consistent with the metabolic improvements observed in the obesity trial — supporting progression to the TRIUMPH-NAFLD Phase 3 trial.

Eli Lilly's Phase 3 development plan for Retatrutide spans six trials. Status as of Q2 2026:

Primary endpoint data for TRIUMPH-1 (obesity) and TRIUMPH-3 (obesity + cardiovascular disease) are anticipated in late 2026 to mid-2027 per Eli Lilly investor guidance. SYNERGY-OUTCOMES — the cardiovascular outcomes MACE trial parallel to Semaglutide's SELECT — follows a longer timeline extending through 2028. TRIUMPH-2 (sleep apnoea), TRIUMPH-4 (adolescents), and TRIUMPH-NAFLD will report on staggered timelines through the same window.

The Australian research community has direct participation in two of the six TRIUMPH trials as of 2026:

• TRIUMPH-3 (obesity + cardiovascular disease, NCT05882077): The University of Sydney Boden Initiative is listed as an active enrolment site. The Boden Initiative for Obesity, Nutrition, Exercise and Eating Disorders is the University's clinical research group focused on metabolic disease intervention research.
• SYNERGY-OUTCOMES (cardiovascular outcomes MACE, NCT06077864): Multiple Australian cardiology centres participate in the multi-centre cardiovascular outcomes trial. The site list at clinicaltrials.gov is the authoritative current registry; site participation can change as the trial progresses.

Australian researchers not directly enrolled as Phase 3 investigators continue to work with research-grade Retatrutide through laboratory channels — receptor pharmacology assays, dose-response studies, mechanism investigations, and protocol-development research that does not require human-trial enrolment.

Both pathways (Phase 3 enrolment and research-grade laboratory work) are governed by distinct regulatory frameworks under the TGA, discussed below.

Retatrutide research sits in context against the broader GLP-1 receptor agonist class. The two most-cited comparator compounds are Tirzepatide (dual GLP-1/GIP agonist) and Semaglutide (single GLP-1 agonist). All three compounds engage GLP-1R; the differentiator is which additional receptors are co-engaged.

Important methodological note: the figures above are cross-trial, not head-to-head. The three compounds were studied in different populations with different durations, dose schedules, and trial designs. Direct ranking (e.g. "Retatrutide is X% more effective than Tirzepatide") is not statistically supportable from these data. The mechanistic distinction (triple vs dual vs single receptor engagement) is the more defensible comparison axis.

No head-to-head trial of Retatrutide vs Tirzepatide has been conducted. Both compounds are developed by Eli Lilly, creating commercial-cannibalisation disincentive against direct comparison. Phase 3 TRIUMPH outcomes will provide better-controlled context once published.

The mechanistic distinction underlying Retatrutide is engagement of three receptors that have historically been studied separately:

1. GLP-1R — drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety via hypothalamic and brainstem pathways. The single-receptor mechanism engaged by Semaglutide.
2. GIPR — amplifies beta-cell insulin secretion through pathways distinct from GLP-1R, modulates adipose lipid handling, and appears to dampen the GI adverse-event signal that GLP-1R agonism alone produces. Added by Tirzepatide as the "twincretin" design.
3. GcgR — drives hepatic fatty-acid oxidation and thermogenesis, increasing resting energy expenditure. Unique to Retatrutide among the three primary research-grade GLP-1 class peptides.

The third receptor (GcgR) is the conceptual addition unique to Retatrutide. Glucagon receptor agonism in isolation would raise blood glucose — but Retatrutide's simultaneous GLP-1R co-agonism drives compensating insulin secretion. The net glycaemic effect in Phase 2 was glucose-lowering, not glucose-raising — meaning the thermogenic benefit of GcgR is captured without the glycaemic downside.

Detailed receptor entity references: GLP-1 Explained, GIP Receptor Explained, Glucagon Receptor Explained.

GI events dominate the Phase 2 adverse event profile, consistent with the GLP-1 class. At the 12mg cohort over 48 weeks:

GI events were dose-dependent and concentrated in the early titration weeks (weeks 1–12). Most resolved with continued dosing or transient dose-step pauses. No cases of pancreatitis, thyroid C-cell tumours, or severe hypoglycaemia were reported in any active cohort. Long-term safety beyond 48 weeks is being characterised in the ongoing Phase 3 TRIUMPH programme — the SYNERGY-OUTCOMES trial collects multi-year safety data across a 17,000+ participant cohort.

Regulatory status under the Therapeutic Goods Administration as of May 2026:

Research-grade Retatrutide is supplied as lyophilised peptide for laboratory research use only. It is not a therapeutic product, not dispensed by prescription, and not interchangeable with approved therapeutic peptide products that may exist in the same class. The two channels (research-grade laboratory supply and approved therapeutic formulation) are governed by distinct TGA frameworks. For full regulatory framing see the dedicated Retatrutide Legal Status in Australia guide.

If Phase 3 TRIUMPH outcomes support regulatory approval, the standard TGA registration pathway would take additional time post-data-publication. As of this report, no public information indicates a confirmed therapeutic approval timeline in Australia.

The window between mid-2026 and end-2027 is the most consequential period for Retatrutide research to date. Anticipated milestones:

• TRIUMPH-1 primary endpoint (obesity) — anticipated late 2026 to early 2027. The first Phase 3 efficacy readout. Confirms or revises the 24.2% mean weight loss observed in Phase 2.
• TRIUMPH-3 primary endpoint (obesity + cardiovascular disease) — anticipated mid-2027. Critical for the cardiovascular co-morbidity context that drives both metabolic-disease epidemiology and the therapeutic-approval framework.
• TRIUMPH-2 (sleep apnoea) and TRIUMPH-4 (adolescents) — staggered readouts through 2026–2027.
• TRIUMPH-NAFLD — primary endpoint timeline beyond the 2026 report window; current sponsor guidance suggests 2027–2028.
• SYNERGY-OUTCOMES (cardiovascular outcomes MACE) — longer trial; primary endpoint anticipated 2028.

For Australian researchers planning protocols against the 2026–2027 readout window, the practical question is which existing research can be designed around the established Phase 2 data versus the anticipated Phase 3 confirmation. Phase 2 data is sufficient for mechanism, receptor-pharmacology, and dose-response research; Phase 3 readouts will be the appropriate reference once available.

This report will be revised within 14 days of any Phase 3 publication per the RetaLABS Research Team update policy. Subsequent editions (2027, 2028) will incorporate the readouts as they publish.

This report was compiled from the following sources, in order of preference per the RetaLABS Research Team sources policy:

1. Peer-reviewed primary clinical trial publications — NEJM, JAMA, Lancet, Nature Medicine, Cell Metabolism, Diabetes Care, Diabetes Obesity & Metabolism. Authoritative for trial methodology, dose, duration, primary endpoint, safety profile, and population demographics.
2. ClinicalTrials.gov NCT registrations — authoritative for ongoing trial design, enrolment, status, and active site lists for Phase 3 trials that have not yet published primary endpoint data.
3. TGA documentation — Australian Register of Therapeutic Goods (ARTG) lookup, the Poisons Standard (SUSMP), and TGA guidance documents. Authoritative for the Australian regulatory status of compounds referenced.
4. Sponsor disclosure — Eli Lilly investor briefings and pipeline updates. Used for current Phase 3 enrolment numbers and projected readout timing when no peer-reviewed publication yet exists.

Numerical claims throughout this report are sourced to one of the above. No claim is made from secondary review articles, marketing copy, social media, or anonymous discussion sources. Cross-trial comparisons are flagged as such throughout; no head-to-head trial result is described as comparative unless it was a controlled head-to-head study.

This report aggregates information already available across the RetaLABS research cluster — the same claims, sourced to the same primary publications, are present in the per-topic articles indexed at Retatrutide Research Papers. The synthesis form (this report) is provided as a single-page reference; the topic articles provide depth on individual sub-topics.

Primary peer-reviewed references for every numerical claim in this report:

1. Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine. 2023; 389:514-526. doi:10.1056/NEJMoa2301972. NCT04881760.
2. Rosenstock J, Frias J, Jastreboff AM, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes." The Lancet. 2023; 402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X.
3. Sanyal AJ, Bedossa P, Fraessdorf M, et al. "Triple Hormone Receptor Agonist Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease." Nature Medicine. 2024; 30:2037-2048.
4. Coskun T, Urva S, Roell WC, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss." Cell Metabolism. 2022; 34(9):1234-1247. doi:10.1016/j.cmet.2022.07.013.
5. Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021; 384:989-1002. doi:10.1056/NEJMoa2032183. NCT03548935.
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022; 387:205-216. doi:10.1056/NEJMoa2206038. NCT04184622.
7. Marso SP, Bain SC, Consoli A, et al. "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes." New England Journal of Medicine. 2016; 375:1834-1844. doi:10.1056/NEJMoa1607141.
8. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." New England Journal of Medicine. 2023; 389:2221-2232. doi:10.1056/NEJMoa2307563.
9. Coskun T, Sloop KW, Loghin C, et al. "LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus." Molecular Metabolism. 2018; 18:3-14.
10. ClinicalTrials.gov: NCT04881760 (Phase 2 obesity), NCT05882045 (TRIUMPH-1), NCT05882049 (TRIUMPH-2), NCT05882077 (TRIUMPH-3), NCT05989711 (TRIUMPH-4), NCT06077864 (SYNERGY-OUTCOMES), NCT06324877 (TRIUMPH-NAFLD).
11. Therapeutic Goods Administration (TGA). Australian Register of Therapeutic Goods (ARTG) lookup; Poisons Standard (SUSMP). tga.gov.au.
12. Eli Lilly & Company. Investor disclosures and pipeline updates. investor.lilly.com.

For an indexed reference card with summaries of each publication, see the Retatrutide Research Papers primary source index.

This report may be cited as:

RetaLABS Research Team. "Retatrutide Research in Australia: 2026 Annual Report." RetaLABS, 25 May 2026. https://www.retalabs.is/research/retatrutide-australia-report-2026.

For corrections, source-verification questions, or methodology queries, contact support@retalabs.is. The full editorial methodology and update policy are documented at the RetaLABS Research Team profile.